# Trial Comparing Immediate Versus Extended Release Tacrolimus; Reducing Calcineurin Inhibitor Related Toxicity in Lung Transplantation Patients

Study · id `cardio:ct-nct05001074` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05001074](<https://clinicaltrials.gov/study/NCT05001074>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05001074

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 145 participants.

## Technical summary

Registry record NCT05001074. Randomized; no masking; primary purpose treatment. Start 2020-07-28 (actual); primary completion 2024-08-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 145 participants (planned count; ClinicalTrials.gov record NCT05001074, source copy `cardio:ctgov-nct05001074-2023-05-10`, retrieved 2026-10-26)
- Started: 2020-07-28 (actual) (ClinicalTrials.gov record NCT05001074, source copy `cardio:ctgov-nct05001074-2023-05-10`, retrieved 2026-10-26)
- Primary completion: 2024-08-01 (anticipated) (ClinicalTrials.gov record NCT05001074, source copy `cardio:ctgov-nct05001074-2023-05-10`, retrieved 2026-10-26)
- Completion: 2024-08-01 (anticipated) (ClinicalTrials.gov record NCT05001074, source copy `cardio:ctgov-nct05001074-2023-05-10`, retrieved 2026-10-26)
- Countries: Netherlands (ClinicalTrials.gov record NCT05001074, source copy `cardio:ctgov-nct05001074-2023-05-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05001074-2023-05-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Trial Comparing Immediate Versus Extended Release Tacrolimus; Reducing Calcineurin Inhibitor Related Toxicity in Lung Transplantation Patients
- Acronym: REVOLUTION
- Condition: Lung Transplant; Complications
- Intervention (Drug): Extended release tacrolimus
- Intervention (Drug): Immediate release tacrolimus
- Lead sponsor: Heleen Grootjans
- Lead sponsor class: OTHER
- Collaborator: Chiesi Farmaceutici S.p.A.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as a collaborator: Chiesi Farmaceutici S.p.A. (`cardio:org-chiesi-farmaceutici-s-p-a`)

## Provenance

Content hash: 63263b2927cb5b708f8f1a4cc6a6c0026c4c21599c731d21a4641c0c9e013d44
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
